Medicortex Finland Oy Announces Issuance of a Patent for Brain Injury Biomarker
16.4.2020 09:55:00 EEST | Business Wire | Press release
Medicortex Finland Oy, an innovative biopharmaceutical company focused on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the European Patent Office (EPO) has issued a patent covering company’s new diagnostic kit technology.
“We are extremely pleased with the growth of the patent portfolio related to the TBI testing. This new issuance continues to expand the intellectual property portfolio covering methods to be used for detection of concussion biomarkers. The issuance of this patent is another step in the development of a robust patent portfolio relating to a new strategy to help identify mild TBI” said Dr. Harel Adrian, Chief Executive Officer of Medicortex.
Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid test will fulfill the urgent need to improve the detection of brain injury especially in mild cases – which are potentially harmful but admittedly difficult to diagnose with the contemporary means. The issued patent covers the core technology and method of utilizing glycan-based biomarkers for detection of mild traumatic brain injury, which is presently the company’s main development program.
Medicortex’s patent portfolio comprises of biomarkers for brain injury diagnostics and drug candidates for halting the progression of brain injury. All innovations have been developed by the company. The comprehensive patent coverage secures exclusivity to develop the products, and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) in 2014, and the company is based in Turku, Finland.
Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial, new patent
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005854/en/
Contact information
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 14:30:00 EEST | Press release
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise. The transaction is subject to customary closing conditions,
Organigram Reports Record Third Quarter Fiscal 2026 Results11.8.2026 13:00:00 EEST | Press release
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”). Q3 FISCAL 2026 HIGHLIGHTS Gross Revenue: $145.1 million (+32% year-over-year). Net Revenue: $105.8 million (+49% year-over-year). Adjusted EBITDA1: $13.4 million (+136% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #4 in beverages2. Sanity Group: Since the acquisition closed on April 15, 2026, Sanity has performed in line with management's expectations, contributing approximately €25 million (C$40 million) in net revenue to Organigram's consolidated results. During the quarter, Sanity continued to execute on its European growth strategy, advancing pr
L&T Technology Services Launches AgenticIQ™, an End-to-End Agentic AI Platform for Engineering, Manufacturing and Customer Experience11.8.2026 12:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of AgenticIQ™, an end-to-end Agentic AI platform purpose-built for engineering and manufacturing organizations. Designed to help enterprises move beyond isolated AI pilots, AgenticIQ™ enables autonomous, multi-agent workflows across engineering, product development, manufacturing, industrial operations and customer experience, accelerating the adoption of Engineering Intelligence at scale. As enterprises increase investments in AI, many initiatives continue to struggle to move beyond proof-of-concepts into production. Disconnected engineering systems, manual processes and highly regulated environments often prevent organizations from scaling autonomous AI while maintaining governance, security and operational reliability. Built on LTTS' portfolio of Engineering Intelligence solutions, AgenticIQ™ transforms proven engineering capa
Naser Taher Named Among Forbes Middle East’s Top 100 CEOs 202611.8.2026 12:00:00 EEST | Press release
MultiBank Group, one of the world’s largest and most regulated financial derivatives institutions, has announced that its Founder and Chairman, Naser Taher, has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811229836/en/ Naser Taher has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. The annual Forbes Middle East Top 100 CEOs list celebrates prominent business leaders who are shaping the region’s corporate landscape and leading organisations with significant scale, influence and impact. The ranking brings together senior executives from across key industries in the Middle East, highlighting their leadership and the performance and development of the organisati
teamLab Unveils New Series from Light Sculpture - Flow at teamLab Borderless. Special Exhibit, "On the Asymmetry of the Universe," on View Through October 811.8.2026 12:00:00 EEST | Press release
teamLab reopens the Light Sculpture - Flow series artwork space at teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Azabudai Hills, Tokyo from July 8, 2026. To commemorate the reopening, teamLab unveils two new series, Asymmetric Existence and Chromatic Existence, featured in the special exhibit "On the Asymmetry of the Universe." The special exhibit, “On the Asymmetry of the Universe,” runs from Wednesday, July 8, 2026 through Thursday, October 8, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807256066/en/ Light Sculpture - Flow The inside and outside of an ocean vortex are composed of the same water; there is no material difference between them. Yet, despite this, why do we perceive a vortex as a singular entity, or even sense a form of life within it? The difference between the inside and outside of a vortex lies in the order, not the material. When order is born within a flow, existence emerges even with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom